BCLI - הכנסה תפעולית לפני ניכוי פחת BrainStorm Cell Therapeutics

Brainstorm Cell (BCLI) is developing cell therapy to combat ALS while facing risks of clinical trial failure and capital shortages. The business's stable humanitarian status minimizes external threats, and the GURU.Markets service calculates quarterly EBITDA, where the figure remains around . However, geopolitical fractures and sanctions could complicate the international logistics of biomaterials and slow down global development.

Brainstorm Cell (BCLI) strategic alliances in NurOwn cell therapy reduce merger risks by creating synergy with leading clinics. An analysis of the EBITDA metric digitizes this process by measuring real operating cash flow excluding depreciation and taxes, allowing investors to compare the current cost of capital with historical retrospectives to identify asset overvaluation.